In this special meeting edition of the Cardiocast, MDedge Cardiology editor Catherine Hackett is joined by MDedge reporters Mitchel L. Zoler, Bruce Jancin, and Richard Mark Kirkner.
The MDedge cardiology team reviews three big stories from the 2019 annual scientific sessions of the American Heart Association in Philadelphia.
* * *
Help us make this podcast better! Please take this short listener survey: https://www.surveymonkey.com/r/podcastsurveyOct2019
* * *
ISCHEMIA trial hailed as practice changing
The results of the ISCHEMIA trial were emphatically declared practice changing by interventional cardiologists and noninterventionalists alike at the AHA meeting.
Bruce Jancin discusses the story.
DAPA-HF: Dapagliflozin's HFrRF efficacy confirmed in nondiabetes
The results in nondiabetics from the practice-changing DAPA-HF trial gives clinicians strong evidence that the diabetes drug dapagliflozin is equally effective at reducing cardiovascular death and acute exacerbations in heart failure patients regardless of diabetes status.
Mitchel L. Zoler discusses this report.
Weakness exposed in valsartan recall
ED visits for hypertension in the month after the 2018 recall spiked 55%. The 2018 recall of generic forms of the antihypertensive drug valsartan exposed weaknesses in the recall systems for generics in both the U.S. and Canada that caused many patients who were on the drug to fall through the cracks.
Richard Mark Kirkner goes deeper into this story.
* * *
For full coverage of AHA 2019 visit MDedge Cardiology
For more MDedge Podcasts, go to mdedge.com/podcasts
Email the show: podcasts@mdedge.com
Interact with us on Twitter: @MDedgeCardio
CV cost of smoking lasts a quarter century
Two FDA approvals, smoking impacts CV health for 25 years
NSAIDS mediate CV risk and hypertension linked to dementia
AI for AFib and acupuncture for angina
Seven simple rules of heart failure risk - you only need two
Air pollution correlated with cardio mortality; statins crush early seizure risk
Half of sudden cardiac deaths linked to silent MI; Uncontrolled hypertension and dementia
Omega-3s cut heart failure; Fat-but-fit theory takes a hit
Lipoprotein(a) levels and genes boost ischemic stroke risk
Continue using paclitaxel-eluting PAD devices
CHD sped cognitive decline; choosing an antidiabetic for elderly patients
Aspirin benefits, risks; Medicaid expansion and CV risks
FFR changes coronary management; doctors want FDA out of the weeds
Novel cardiogenic shock nets survival, plus does ethnicity affect predisposition to components of metabolic syndrome?
Definition of carcinogenic shock
Infection risk for cardiac rhythm device
Stroke risk, DOAC type in nonvalvular A-Fib patients
Heightened stroke risk with long-term antibiotics?
ACC 2019 Reporter's Breakdown
Plant-based diet lowers risk of heart failure
Create your
podcast in
minutes
It is Free
Good Mood Revolution
The Relaxback UK Show
On Call With Dr. Anselm Anyoha
Precision Medicine Forum Podcast
The Doctor’s Farmacy with Mark Hyman, M.D.
The Peter Attia Drive